CAS: 3619-73-6; 1-Ethyl-1,4-Diazepane

相似化合物

4410-12-2 4318-37-0 1219843-83-0

上下游产品

CAS号61903-11-5 N-乙酰基高哌嗪 | CAS号505-66-8 高哌嗪 | CAS号75-03-6 碘乙烷

📜1-(Benzyl Carboxy)-4-Ethyl-Homopiperazine置于palladium 10% On Activated Carbon,氢气体系中,用 乙酸乙酯 用作溶剂,化学反应 17.0H,反应生成1-乙基高哌嗪
参考文献: Method For Use Of Homopiperazinium Compounds In The Treatment Of Cancer[fr] Méthode D'Utilisation De Composés D'Homopipérazinium Dans Le Traitement Du Cancer
标题: Method For Use Of Homopiperazinium Compounds In The Treatment Of Cancer[fr] Méthode D'Utilisation De Composés D'Homopipérazinium Dans Le Traitement Du Cancer
摘要:本公开涉及一种治疗癌症的方法,包括向有需要的患者施用具有以下化学式的化合物的有效量:(化学式(i)),其中r1,R2,Ya,Xa和j-如本文所定义.

专利信息

专利号:US-6407103-B2
优先权日:1998-04-21
标 题:Indeno [1,2-c] pyrazol-4-ones and their uses
发明人：NUGIEL DAVID A; CARINI DAVID J; DI MEO SUSAN V; YUE EDDY W
权利人:BRISTOL MYERS SQUIBB PHARMA CO
摘要:The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I):that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H.This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

专利号:WO-2015110467-A1
优先权日:2014-01-23
标 题:Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides
发明人：ARCARI ALESSANDRO; D ARASMO GERMANO; LOMBARDI BORGIA ANDREA
权利人:NERVIANO MEDICAL SCIENCES SRL
摘要:The present invention relates to a process for the preparation of substituted N-(5-benzenesulfonyl-1 H-indazol-3-yl)-benzamides and to the useful intermediate compounds of such process. Such derivatives are described and claimed in WO2008/074749, which also discloses processes for their preparation. The process of the present invention allows to obtain the desired products in high yields and purity and with a limited number of steps. The synthesis starts from 5-iodo-1 H-indazol-3-ylamine and comprises, as the key steps, the coupling of an activated benzoic acid with a 5-phenylsulfanyl-1 H-indazol-3-ylamine scaffold and the subsequent oxidation of the sulfur atom, followed by further functional group transformations, which furnish the desired products. The compounds prepared according to the process of the present invention are endowed with protein kinase inhibiting activity and, more particularly, IGF-1R or ALK inhibiting activity. The compounds are therefore useful in the treatment of a variety of cancers, cell proliferative disorders and diseases associated with protein kinases.